Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melinda L Telli

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|August 25, 2011
PARP inhibitors in cancer: moving beyond BRCAMelinda L Telli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancerMelinda L Telli
The Lancet. Oncology|August 31, 2020
BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?Melinda L Telli
Clinical Breast Cancer|July 1, 2010
Novel treatment approaches for triple-negative breast cancerMelinda L Telli, James M Ford
Clinical Advances in Hematology & Oncology : H&O|December 16, 2010
PARP inhibitors in breast cancerMelinda L Telli, James M Ford
Clinical Breast Cancer|July 15, 2009
First-line chemotherapy for metastatic breast cancerMelinda L Telli, Robert W Carlson
Journal of Molecular Medicine (Berlin, Germany)|January 9, 2015
The future of breast cancer systemic therapy: the next 10 yearsMelinda L Telli, George W Sledge
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2011
Trastuzumab-related cardiac dysfunctionMelinda L Telli, Ronald M Witteles
Journal of Oncology Practice|May 11, 2017
Outstanding Questions in the Clinical Management of Triple-Negative Breast CancerJoshua J Gruber, Melinda L Telli
Oncology (Williston Park, N.Y.)|December 18, 2016
Breast Cancer After Hodgkin Lymphoma: The Price of SuccessVeronica Manzo, Frederick Dirbas, Melinda L Telli
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|August 25, 2011
PARP inhibitors in cancer: moving beyond BRCAMelinda L Telli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancerMelinda L Telli
The Lancet. Oncology|August 31, 2020
BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?Melinda L Telli
Clinical Breast Cancer|July 1, 2010
Novel treatment approaches for triple-negative breast cancerMelinda L Telli, James M Ford
Clinical Advances in Hematology & Oncology : H&O|December 16, 2010
PARP inhibitors in breast cancerMelinda L Telli, James M Ford
Clinical Breast Cancer|July 15, 2009
First-line chemotherapy for metastatic breast cancerMelinda L Telli, Robert W Carlson
Journal of Molecular Medicine (Berlin, Germany)|January 9, 2015
The future of breast cancer systemic therapy: the next 10 yearsMelinda L Telli, George W Sledge
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2011
Trastuzumab-related cardiac dysfunctionMelinda L Telli, Ronald M Witteles
Journal of Oncology Practice|May 11, 2017
Outstanding Questions in the Clinical Management of Triple-Negative Breast CancerJoshua J Gruber, Melinda L Telli
Oncology (Williston Park, N.Y.)|December 18, 2016
Breast Cancer After Hodgkin Lymphoma: The Price of SuccessVeronica Manzo, Frederick Dirbas, Melinda L Telli
Pageof 9